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biloba, and pycnogenol. Half of the studies focused on breast cancer. Most resulted in 
statistically non-significant findings, but two studies of erythpoietin and the pycnog-
enol trial had significant results. All 3 of the non-pharmacological studies focused on 
patients with breast cancer, two using a form of cognitive-behavior therapy (CBT) and 
the third studying a yoga program. CONCLUSIONS: The review found a large number 
of studies documenting the problem of CRCD, discussing innovative ways of measur-
ing the extent of the cognitive impairment, and describing etiological theories, such 
as the relationship of CRCD to fatigue and anemia. However, there was a paucity of 
well-designed, sufficiently powered studies of potential treatments, given the extent 
of the problem and its impact on patient functioning. This is an area of clear patient 
need which warrants further scientific study.
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OBJECTIVES: To evaluate short and long term effects of hypofractioned radiation 
therapy in women with early stage breast cancer, after undergoing breast con-
servative surgery. METHODS: We searched for randomized controlled trials in 
Embase, Medline, Cochrane Library and Lilacs comparing unconventional versus 
conventional fractioning. The authors performed data extraction independently. 
Disagreements were resolved by consensus. Random-effects risk ratios (RR) were 
calculated comparing patients randomized to unconventional with those to con-
ventional fractioning. Periods before and after five years of treatment were consid-
ered. RESULTS: Five trials reported on 7.802 women. The studies were of medium to 
high quality. Unconventional fractionation did not affect, until five years and after 
five years, respectively: (1) local recurrence RR 0.90 (95% CI 0.68 to 1.18, P = 0.44) and 
RR 0.98 (95% CI 0.83 to 1.17, P = 0.86); (2) distant recurrence (RR) 1.04 (95% CI 0.73 to 
1.46, P = 0.84) and RR 1.02 (95% CI 0.79 to 1.32, P = 0.88); (3) mortality RR 0.89 (95% 
CI 0.77 to 1.05, P = 0.16) and RR 0.96 (95% CI 0.89 to 1.08, P = 0.48); (4) disease-free 
survival RR 0.96 (95% CI 0.78 to 1.18, P = 0.69) and RR 0.96 (95% CI 0.84 to 1.09, P = 
0.49); (5) cardiac ischemia RR 0.73 (95% CI 0.34 to 1.57, P = 0.42) and RR 0.61 (95% CI 
0.33 to 1.15, P = 0.13); (6) rib fracture RR 1.02 (95% CI 0.25 to 4.20, P = 0.98) and RR 1.08 
(95% CI 0.26 to 4.53, P = 0.91); (7) pulmonary fibrosis RR 2.42 (95% CI 0.50 to 11.71, 
P = 0.27) and RR 0.97 (95% CI 0.89 to 11.21, P = 0.07). CONCLUSIONS: Using hypof-
ractioned radiotherapy regimens does not affect any of the outcomes analyzed in 
women with early stage breast cancer, after undergoing breast conservative surgery.
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OBJECTIVES: The purpose of this study was to estimate incidence of and identify fac-
tors associated with cardiotoxicity, defined as heart failure and/or cardiomyopathy, 
and all-cause mortality in breast cancer patients undergoing adjuvant chemotherapy 
or hormones. METHODS: A retrospective, population-based cohort study of 108,672 
women (≥ 66 years of age) newly diagnosed with breast cancer from 2001-2009 was 
conducted using the Surveillance, Epidemiology, and End Results (SEER)-Medicare-
linked database. Adjuvant chemotherapy were classified as mutually exclusive 
groups: trastuzumab-based, anthracycline-based, anthracycline and trastuzumab-
based, taxane-based, and other chemotherapy. Propensity score matching adjusted for 
differences in patient characteristics across treatments. The final sample included a 
total of 11,250 women. Multivariable Cox proportional hazards regression models esti-
mated hazard ratios (HRs) of cardiotoxicity and all-cause mortality with adjustment 
for inverse probability weights, sociodemographics, cancer characteristics, comorbidi-
ties, surgery and radiation, region, and year at diagnosis. RESULTS: Compared with 
hormones, risk of cardiotoxicity was higher in patients treated with anthracycline 
and trastuzumab-based (adjusted HR= 1.87; 95% confidence intervals [CI]= 1.51-2.33), 
trastuzumab-based (HR= 1.32; 95%CI= 1.14-1.52), and anthracycline-based (HR= 1.14; 
95%CI= 1.03-1.27) regimens, respectively. Certain baseline characteristics were sig-
nificant predictors of cardiotoxicity, including demographics (older age (vs. ≤ 70), 
non-Hispanic black), cancer characteristics (advanced stage), comorbidities (cardio-
vascular conditions or renal failure), year at diagnosis, and West region (vs. Northeast). 
Additionally, risk of all-cause mortality was higher in patients treated with taxane-
based (HR= 1.54; 95%CI= 1.43-1.67) regimens compared to hormones. Baseline charac-
teristics including sociodemographics, cancer characteristics, cardiovascular or renal 
failure comorbid conditions, year at diagnosis, and South region were significant pre-
dictors of all-cause mortality (all P< 0.05). CONCLUSIONS: Women with breast cancer 
treated with trastuzumab-based and/or anthracycline-based regimens had increased 
cardiotoxicity risk compared with hormones, while those treated with taxane-based 
regimens had higher rates of all-cause mortality. Types of chemotherapy are associ-
ated with increased risk of cardiotoxicity and all-cause mortality. Practitioners should 
further evaluate treatment and patient characteristics for risk mitigation strategies.
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OBJECTIVES: Although the relationship between diabetes and risk of pancreatic 
cancer are well-documented, limited research has examined whether racial/eth-
nicity differences accounted for the association between diabetes and pancreatic 
cancer. The aims of this study were to 1) assess whether diabetes is associated with 
pancreatic cancer in the elderly Medicare population, and 2) identify if any racial/
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OBJECTIVES: Denosumab is a biologic approved in June 2010 to treat bone tumors 
and hypercalcemia of malignancy. This study characterizes bone-related safety sig-
nals of subtrochanteric atypical femoral fractures (SAF) and osteonecrosis of the 
jaw (ONJ) in relation to denosumab therapy. METHODS: The FDA Adverse Event 
Reporting System was used to detect signals of SAF and ONJ in relation to deno-
sumab therapy. Adverse event reports submitted between July 2010 and December 
2013 were retrieved and disproportional reporting of SAF and ONJ was calculated by 
Empirical Bayes Geometric Mean (EBGM). Denosumab-event pairs with EBGM 95% 
confidence interval lower limit ≥ 2.0 are considered signals of SAF and ONJ excess 
reporting compared to other drugs in the database. Events were defined by the 
Preferred Terms of the Medical Dictionary for Regulatory Activities, and denosumab 
was defined by the Anatomical Chemical Therapeutic Classification. RESULTS: A 
total of 26,216 adverse event reports submitted for denosumab during the analysis 
period, corresponding to 30 for SAF and 721 for ONJ. Denosumab was significantly 
associated with more than expected reporting of SAF (EBGM= 17.5, 95%CI= 9.67-30.0) 
and ONJ (EBGM= 26.9, 95%CI= 20.1-35.9) compared to other drugs. The majority of 
denosumab users who experienced both events were females, and average age was 
69 years (SAF SD= 9.5; ONJ SD= 11.3). 12 SAF and 65 ONJ events lead to hospitaliza-
tion; 25 and 14 ONJ events contributed to patient disability and death, respectively. 
Other factors could have lead to these serious outcomes, including comedications 
and comorbidities. CONCLUSIONS: SAF and ONJ are potential risks of denosumab 
therapy. Patients with thigh or hip pain should seek immediate medical help, and 
periodic dental and maxillofacial evaluations should be performed before and dur-
ing denosumab therapy. Pharmacoepidemiologic studies are recommended to fur-
ther characterize these risks, as some patients were treated with other medications, 
including systemic corticosteroids at the time of event occurrence.
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OBJECTIVES: Sipuleucel-T is an autologous active cellular immunotherapy designed 
to reduce the risk of death in patients with prostate cancer. The aim of this study was 
to evaluate the safety of Sipuleucel-T for patients with prostate cancer. METHODS: 
PubMed, EMBASE and the Cochrane Central Register of Controlled Trials were 
searched through January 10, 2015. Criteria for inclusion were randomized, pla-
cebo-controlled clinical trials on Sipuleucel-T, patients receiving three infusions, 
36 months follow-up and the availability of outcomes data for adverse events. The 
primary outcome was the total number of adverse events. Secondary outcomes 
examined eighteen specified adverse events. Two investigators selected studies 
independently and assessed the quality of studies using the Jadad scale. Point esti-
mates with a 95% confidence interval were generated. Fixed-effects or random 
random-effects models were based on the evaluation of heterogeneity. RESULTS: 
Five clinical trials encompassing 1031 patients were included. The overall adverse 
events relative risk (RR) was 1.02 (95% CI 1.00 to 1.05, p= 0.091). For the secondary 
outcomes, differences were detected between Sipuleucel-T and placebo on chills (RR 
4.87; 95% CI 2.50 to 6.78, p= 0.000; 904 patients), fatigue (RR 1.20; 95% CI 1.01 to 1.43, 
p= 0.035; 1031 patients), pyrexia (RR 5.40; 95% CI 1.90 to 15.35, p= 0.002; 1031 patients), 
headache (RR 2.68; 95% CI 1.75 to 4.10, p= 0.000; 1031 patients), influenza like illness 
(RR 3.07; 95% CI 1.48 to 6.36, p= 0.003; 681 patients), myalgia (RR 2.24; 95% CI 1.26 
to 4.00, p= 0.006; 681 patients), nausea (RR 1.40; 95% CI 1.05 to 1.88, p= 0.023; 1031 
patients), vomiting (RR 1.86; 95% CI 1.21 to 2.88, p= 0.005; 856 patients) and dyspnea 
(RR 3.72; 95% CI 1.34 to 10.36, p= 0.012; 350 patients). CONCLUSIONS: Sipuleucel-T 
significantly increased the risk of selected adverse events in patients with prostate 
cancer. Although many adverse events were transient, patients and providers should 
consider the potential risk of treatment with Sipuleucel-T.
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OBJECTIVES: Chemotherapy-related cognitive dysfunction (CRCD), colloquially known 
as ‘chemo fog’ or ‘chemo brain,’ describes the impact of chemotherapy on cogni-
tive functioning in domains ranging from memory to expressive language. CRCD is 
generally attributed to the direct or indirect effects of chemotherapy on the central 
nervous system, may occur at some level of intensity in as many as 75% of patients 
who have undergone chemotherapy, and impacts patient quality of life, educational/
occupational achievement, and social functioning. Management of CRCD includes 
both pharmacological and non-pharmacological therapies. METHODS: To better 
understand the range of treatments that have been studied for CRCD, and their rela-
tive efficacy, a comprehensive review of the published literature was undertaken. A 
MEDLINE search was conducted for relevant sources published in English between 
January 2005 and December 2014. The search was limited to studies describing tri-
als of interventions to manage or treat CRCD using non-pharmacological interven-
tions. RESULTS: Of 161 records retrieved, 11 described interventions targeting CRCD. 
Pharmacological therapies used included erythropoietin, dexmethylphenidate, ginkgo 
